Afatinib

Drug #2314

Afatinib is a tyrosine kinase inhibitor which is a 4-anilinoquinazoline. Afatinib is presented as the dimaleate salt, with the chemical name 2-butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-,(2E)-, (2Z)-2-butenedioate (1:2). It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to quinazolinamines.

It belongs to Tyrosine kinase inhibitor pharmacological group on the basis of mechanism of action.

Molecular Weight: 718.1 · Solubility in Water: souble · Non-proprietary name: afatinib.

Pharmacokinetics

Absorption: Afatinib has an oral bioavailability is 92%.

Distribution: Afatinib has a plasma protein binding is 95%.

Elimination: plasma half-life is 37hrs, renal excretion is 85% by feces4% by urinr.

Indications

Afatinib is primarily indicated in conditions like Non small cell lung cancer.

Contraindications

None recorded.

Dosage

Afatinib's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
40 mg	40 mg	—	PO	Instruct patients to take medication at least 1 hour before or 2 hours after a meal
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

16 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Afatinib is known to cause more or less tolerable side effects which are usually transient. These include Acneform, Dermatitis, Diarrhea, Dry skin, Loss of appetite, Paronychia, Pruritis, Rash, Stomatitis.

Warnings / Precautions

diarrhea,bullous and exfoliative skin disorders, interstitial lung disease, hepatic toxicity, keratitis, embryofetal toxicity. caution should be taken in all these conditions.

Available Brands

None recorded.

Storage Conditions

Afatinib should be stored Tablet.

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs